Bridge Biotherapeutics: 30% or more change in sales or profit/loss (15% or more for large companies)







30% or more change in sales or profit/loss (15% or more for larger companies)

1. Type of financial statements Consolidated financial statements
2. Details of changes in sales or profit/loss (KRW) Current fiscal year Previous exercice Amount increased/decreased Rate of increase/decrease (%)
– Sales (Limited to the amount of revenue based on sales of goods and services provided) 1,924,158,150 6,339,946,467 -4,415,788,317 -70.00
– Operating result -26,391,767,980 -19,578,220,215 -6,813,547,765 -35.00
– Earnings from continuing operations before corporation tax -26 278 291 392 -19,232,492,177 -7,045,799,215 -37.00
– Net revenue -26 278 291 392 -19,232,492,177 -7,045,799,215 -37.00
– Applicability of large-scale society No
3. Financial situation (KRW) Current fiscal year Previous exercice
– Total assets 46,657,249,917 63 510 099 312
– Total responsibilities 3,609,930,975 4,282,024,005
– Total equity 43,047,318,942 59 228 075 307
– share capital 9,853,712,500 9,590,587,000
4. Main reasons for changes in sales or profit/loss 1. Reasons for changes in sales.
Fluctuation in profits due to the company’s business model

2. Reasons for profit and loss change.
Increase in R&D spending due to advancements in the development of the company’s pipeline assets

Increase in stock-based compensation costs.
– Stock options granted to new R&D employees
– Donation of shares by the majority shareholder to the employee shareholding association

5. Board resolution date (decision date) 2022-03-07
– Presence of external directors Present (No.) 3
Absent(No.)
– Presence of the Statutory Auditors (members of the Audit Committee)
6. Other references regarding investment decisions 1. Consolidated financial statements for the current year (2021) are based on K-IFRS

2. The consolidated financial statements for the previous year (2020) are based on the consolidated audit report for the same year.

3. The above content is subject to change after the external audit and the Annual General Meeting of Shareholders.

※ Relevant disclosure
Note that this disclosure includes unaudited information and some details may change based on audit results.

Warning

Bridge Biotherapeutics Inc. published this content on March 08, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on March 08, 2022 01:00:08 UTC.

Public now 2022

All the latest from BRIDGE BIOTHERAPEUTICS, INC.

Sales 2020 6,340M
5.15M
5.15M
Net income 2020 -19,232M
-15.6M
-15.6M
Net cash 2020 57,548M
46.7M
46.7M
2020 PER ratio -14.4x
2020 performance
Capitalization 240B
194M
194M
EV / Sales 2019 4.26x
EV / Sales 2020 34.9x
# of employees 30
Floating

Chart BRIDGE BIOTHERAPEUTICS, INC.


Duration :

Period :




Bridge Biotherapeutics, Inc. Technical Analysis Chart |  MarketScreener



Evolution of the income statement


Comments are closed.